- Home
- OCEAW vs ICFI Comparison
OCEAW vs ICFI Comparison
Compare OCEAW & ICFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCEAW
- ICFI
- Stock Information
- Founded
- OCEAW N/A
- ICFI 1969
- Country
- OCEAW United States
- ICFI United States
- Employees
- OCEAW 7
- ICFI N/A
- Industry
- OCEAW Biotechnology: Pharmaceutical Preparations
- ICFI Professional Services
- Sector
- OCEAW Health Care
- ICFI Consumer Discretionary
- Exchange
- OCEAW Nasdaq
- ICFI Nasdaq
- Market Cap
- OCEAW N/A
- ICFI N/A
- IPO Year
- OCEAW 2021
- ICFI 2006
- Fundamental
- Price
- OCEAW $0.03
- ICFI $100.11
- Analyst Decision
- OCEAW
- ICFI Strong Buy
- Analyst Count
- OCEAW 0
- ICFI 4
- Target Price
- OCEAW N/A
- ICFI $167.25
- AVG Volume (30 Days)
- OCEAW N/A
- ICFI 304.1K
- Earning Date
- OCEAW N/A
- ICFI 02-27-2025
- Dividend Yield
- OCEAW N/A
- ICFI 0.56%
- EPS Growth
- OCEAW N/A
- ICFI 55.44
- EPS
- OCEAW N/A
- ICFI 5.69
- Revenue
- OCEAW N/A
- ICFI $2,001,815,000.00
- Revenue This Year
- OCEAW N/A
- ICFI $4.83
- Revenue Next Year
- OCEAW N/A
- ICFI $7.73
- P/E Ratio
- OCEAW N/A
- ICFI $17.60
- Revenue Growth
- OCEAW N/A
- ICFI 2.11
- 52 Week Low
- OCEAW N/A
- ICFI $97.92
- 52 Week High
- OCEAW N/A
- ICFI $179.67
- Technical
- Relative Strength Index (RSI)
- OCEAW N/A
- ICFI 21.01
- Support Level
- OCEAW N/A
- ICFI $106.02
- Resistance Level
- OCEAW N/A
- ICFI $119.48
- Average True Range (ATR)
- OCEAW 0.00
- ICFI 3.68
- MACD
- OCEAW 0.00
- ICFI -1.44
- Stochastic Oscillator
- OCEAW 0.00
- ICFI 10.16
About OCEAW Ocean Biomediacal Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.